Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Fierce Biotech
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
AstraZeneca is investing $2 billion in Summit to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with ADCs.
Nick Paul Taylor
Sep 29, 2026 3:07am
AstraZeneca’s Etcamah flunks first-line breast cancer trial
Sep 12, 2026 12:43pm
Kelun's sac-TMT win offers blueprint for Merck's global gap
Jul 15, 2026 10:20am
FDA expands Padcev-Keytruda combo to more MIBC patients
Jul 10, 2026 1:10pm
FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
Jul 10, 2026 10:55am
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
Jun 15, 2026 8:25am
